Posted by Michael Wonder on 05 Apr 2018
ICER to assess medication-assisted therapy for treatment of opioid use disorder
5 April 2018 - Report will be subject of November New England CEPAC meeting; open Input now being accepted until 24 April 2018.
The Institute for Clinical and Economic Review (ICER) today announced plans to develop a report assessing the comparative clinical effectiveness and value of several new options for medication-assisted treatment (MAT) of opioid use disorder. The report will be the subject of a public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) in November of 2018.
ICER’s upcoming review will assess the effectiveness and value of a recently-approved monthly buprenorphine injection (Sublocade, Indivior), a buprenorphine implant (Probuphine, Braeburn/Titan), and an investigational buprenorphine extended release injection (CAM2038, Braeburn) currently under review by the FDA, as compared to medications commonly used in MAT such as methadone, buprenorphine/naltrexone sublingual film (Suboxone, Indivior), and injectable naltrexone (Vivitrol, Alkermes). This list is tentative and subject to change.
